TERIPARATIDE (r-hPTH 1-34)

7/31/01


Click here to start


Table of Contents

TERIPARATIDE (r-hPTH 1-34)

Teriparatide

Teriparatide

Principal outcomes

PRECLINICAL DEVELOPMENT PROGRAM

Clinical (Phase 1-2) Studies

GHAC: Effects of teriparatide in the Treatment of Postmenopausal Women with Osteoporosis

GHAC PRIMARY ENDPOINT RESULTS Proportion of patients with 1 or more new vertebral fractures

Other Vertebral Fracture Results (not pre-specified)

Secondary endpoint: New Non-vertebral Atraumatic Fractures Combined

Study GHAC Non-vertebral Fractures by Site

GHAC: other secondary efficacy endpoints

GHAJ: Effects of teriparatide in the treatment of men with primary osteoporosis and osteoporosis associated with primary hypogonadism

GHAJ Treatment Exposure

GHAJ Results

Teriparatide: Clinical Efficacy Summary

Teriparatide: Clinical Efficacy Summary

OSTEOSARCOMA

OSTEOSARCOMA

Osteosarcoma

Osteosarcoma

Osteosarcoma

Osteosarcoma

Osteosarcoma

Osteosarcoma

Osteosarcoma

Teriparatide

Author: Jeanine Vinson